The influence of latent hyperprolactinaemia on the levels of LH, FSH, E2 and T in the midfollicular phase of the cycle
Jazyk angličtina Země Německo Médium print
Typ dokumentu časopisecké články
PubMed
9059746
Knihovny.cz E-zdroje
- MeSH
- antagonisté dopaminu MeSH
- dospělí MeSH
- estradiol krev MeSH
- folikulární fáze fyziologie MeSH
- folikuly stimulující hormon krev MeSH
- hyperprolaktinemie krev diagnóza MeSH
- lidé MeSH
- luteinizační hormon krev MeSH
- metoklopramid MeSH
- mladiství MeSH
- testosteron krev MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mladiství MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- antagonisté dopaminu MeSH
- estradiol MeSH
- folikuly stimulující hormon MeSH
- luteinizační hormon MeSH
- metoklopramid MeSH
- testosteron MeSH
The metoclopramide test for latent hyperprolactinaemia was done on 174 randomly chosen infertile women in the midfollicular phase of the cycle. 54 women had latent hyperprolactinaemia which was defined as a PRL level of at least 150 ng/ml after metoclopramide. Just before the metoclopramide was given, blood was taken to measure the levels of luteinizing hormone (LH) and follicle stimulating hormone (FSH), 17-beta estradiol (E2) and total testosterone (T). Women with latent hyperprolactinaemia had significantly lower levels of LH (p < 0.01) and E2 (p < 0.001) and higher levels of T (p < 0.05) in the midfollicular phase when compared with women without this condition. FSH levels showed no statistically significant difference.
